A17651 Renal denervation for resistant hypertension in patients less than 65-year-old

Abstract

Objectives: To investigate the safety and mid-term efficacy of renal denervation (RDN) in less than 65-year-old Chinese patients with resistant hypertension. Methods: In the prospective cohort study, the patients with resistant hypertension were continuously enrolled to undergo RDN between November 2012 and November 2014 using LEPU single-electrode ablation catheter. The primary effectiveness endpoints were reductions in office blood pressure and 24-hour ambulatory blood pressure (24h-ABP) at six months. The primary safety endpoint was the incidence of major adverse event through 6 months. Results: A total of 50 consecutive patients, aged between 26 and 62 (41.9 ± 10.6) years old, were enrolled, in which 18 (36.0%) were female. At six months after surgery, the office BP and 24-h ABP were separately reduced by 23.7 ± 14.5/11.5 ± 7.9 mmHg and 11.1 ± 8.5/7.1 ± 6.2 mmHg, with the reduction of the number of antihypertensive agents from 4.0 (4.0∼4.0) at baseline to 4.0 (3.0∼4.0) (all P < 0.01). There is no significant change of renal function (P > 0.05) and no major adverse events occurred. Only one patient suffered from femoral artery pseudoaneurysm with no sequelae. Conclusion: RDN seems to be safe and effective in lowering BP in the less than 65-year-old Chinese cohort with resistant hypertension.